IntegriChain delivers the life science industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, managed services and expert advisors to power their operations and harness the value of their channel, patient and payer data.
View all products
To ensure you get the most out of your access and commercialization investment, IntegriChain provides a complete set of professional Advisory and Systems Integration Services designed to further your business and success.
Services overview
IntegriChain provides wide array of resources to help you navigate your journey to market access success.
Resources overview
We help all stakeholders in the life sciences industry drive access. We do this through our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider, pharmacy and patient access insights for our life sciences customers.
Learn more about our company
Keep in touch with IntegrChain through our news and frequent events.
View all news & events
July 16, 2020 | 1:00 pm ET
Watch the Webinar
Access Password: IntegriChain-CEO_Council@20200716
Cell and Gene Therapy companies have unique pricing and contracting strategies that can impact government program access. Join IntegriChain’s Jeff Baab and as the do a “deep-dive” into contracting strategies and considerations. Topics to be explored include:
Along with key market access considerations — such as payer coverage and policy trends — to maximize access to government and commercial channels.
Who should attend: Finance and Accounting Professionals, Contracting & Pricing Professionals, Market Access Executive Leadership
Jeff Baab Josef Magpantay
Watch The Webinar
CEO Council for Growth’s Cell & Gene Therapy and Connected Health Initiative, in partnership with IntegriChain, is pleased to announce a three-part educational webinar series designed specifically for emerging cell and gene therapy (CGT) firms. The focus will be on launch and commercialization preparedness.
Discovery and development are necessarily the focus during the earliest stages of development of CGTs, but careful market access plans are also essential if a therapeutic is to reach as many patients as possible. To support young companies and stimulate overall industry growth in this important subsector of the life sciences, experts from Philadelphia-based IntegriChain, a data and business process platform for therapy commercialization and access, will share their knowledge and experiences via this complimentary educational series running Summer 2020.
